Evidence map›Paper›PMID 28684559›Full record

GuidelineAnnals of the rheumatic diseases2018

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewé, Philip Mease, Joachim Sieper and 27 more

Erratum issuedAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of the rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 266 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

266 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Guideline
  2. Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.The Cochrane database of systematic reviews · 2025
    Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Guideline
  11. Pooled it
  12. Guideline
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors.

Josef S SmolenDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
Monika SchölsHealth Consult, Vienna, Austria.
Jürgen BraunRheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany.
Maxime DougadosDepartment of Rheumatology, Paris Descartes University, Paris, France.
Oliver FitzGeraldDepartment of Rheumatology, St Vincent's University Hospital, Dublin, Ireland.
Dafna D GladmanDivision of Rheumatology, University of Toronto, Toronto, Ontario, Canada.
Arthur KavanaughDivision of Rheumatology, University of California, San Diego, CA, USA.
Robert LandewéAmsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands.
Philip MeaseDivision of Rheumatology Research, Swedish-Providence St. Joseph Health System, University of Washington, Seattle, WA, USA.
Joachim SieperDepartment of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany.
Tanja StammSection for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Maarten de WitDepartment of Medical Humanities, VU University Medical Centre, Amsterdam, The Netherlands.
Daniel AletahaDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
Xenofon BaraliakosRheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany.
Neil BetteridgeNeil Betteridge Associates, UK.
Filip van den BoschGhent University Hospital, Ghent, Belgium.
Laura C CoatesDepartment of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Paul EmeryLeeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
Lianne S GenslerDepartment of Medicine, University of California, San Francisco, CA, USA.
Laure GossecDepartment of Rheumatology, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France.
Philip HelliwellInstitute of Molecular Medicine, University of Leeds, Leeds, UK.
Merryn JongkeesSeayn Medical, Voorschoten, The Netherlands.
Tore K KvienDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Robert D InmanUniversity Health Network and University of Toronto, Toronto, Ontario, Canada.
Iain B McInnesUniversity of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, UK.
Mara MaccaroneA.DI.PSO. (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Rome, Italy.
Pedro M MachadoCentre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, UK.
Anna MoltoDepartment of Rheumatology, Paris Descartes University, Paris, France.
Alexis OgdieDivision of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA.
Denis PoddubnyyDepartment of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany.
Christopher RitchlinAllergy, Immunology and Rheumatology Division, University of Rochester Medical Center Rochester, New York, NY, USA.
Martin RudwaleitDepartment of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany.
Adrian TanewDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Bing ThioDepartment of Dermatology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.
Douglas VealeDepartment of Rheumatology, Klinikum Bielefeld, Bielefeld, Germany.
Kurt de VlamDivision of Rheumatology, University Hospitals Leuven, Leuven, Belgium.
Désirée van der HeijdeDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

Arthritis Research UK 18475Department of Health CS-2016-16-016Department of Health RC-PG-0407-10054Versus Arthritis 18825Versus Arthritis 20639
6 · The paper itself

Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

Indexed as

Severity of Illness IndexAdvisory CommitteesArthritis, PsoriaticAxis, Cervical VertebraConsensusDecision MakingHumansSpondylitis, AnkylosingAnkylosing SpondylitisOutcomes ResearchPsoriatic ArthritisSpondyloarthritisTreatment

Identifiers

PMID28684559
PMCPMC5754738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.